Thermo Fisher Scientific Inc.
TMO
$717.71
-0.07%
Thermo Fisher Scientific is the world's largest pure-play life sciences tools and diagnostics company, selling analytical instruments, laboratory equipment, specialty diagnostics, life science reagents, and CRO services through four reporting segments — analytical technologies (17% of sales), specialty diagnostics (11%), life science solutions (23%), and lab products and services including CRO (the remainder). Its scale, breadth of portfolio, and entrenched customer relationships across pharma, biotech, academic, and industrial end markets make it the closest thing to a 'picks-and-shovels' platform in the life sciences ecosystem, with a consumables-heavy revenue mix that generates recurring, high-visibility cash flow. The current investor narrative centers on a re-acceleration story: after a multi-year post-pandemic destocking hangover, revenue growth has returned to high-single digits, management has raised guidance, and commentary around AI-driven internal efficiencies and productivity has reinforced the margin-expansion thesis. Recent coverage highlights raised long-term guidance and operational resilience even as the company flags 'modest inflation' risk tied to Middle East tensions, framing TMO as a durable compounder whose earnings quality is being re-rated by the market.…
TMO
Thermo Fisher Scientific Inc.
$717.71
Related headlines
Investment Opinion: Should I buy TMO Today?
Rating: Buy (accumulate on weakness). Thermo Fisher is a high-quality, low-beta (0.845) life sciences compounder whose fundamentals have genuinely re-accelerated — Q3 2026 revenue of $12.137 billion grew 9.13% YoY, gross margin expanded ~210bps from 40.67% in Q1 to 42.78% in Q3, and free cash flow reached $7.596 billion — while 23 of 25 analysts rate it Buy with a 'strong_buy' consensus and a $752.12 average target implying +8.3% upside from $694.76. The core thesis is that TMO's recurring consumables-and-services mix (services $5.384B plus consumables $4.870B versus instruments of just $1.883B) plus operating leverage from AI-driven productivity can sustain high-single-digit growth and margin expansion toward the low-20s operating level, justifying a premium multiple.
Supporting evidence is broad: forward PE of 25.0x versus trailing 32.6x implies ~23% earnings growth embedded in consensus EPS of $37.24, revenue is compounding sequentially ($11.005B → $11.994B → $12.137B across Q1–Q3 2026), operating margin climbed from 16.93% to 18.65% over the same span, trailing FCF of $7.596 billion yields ~3.5% of the $217.9 billion market cap, and the stock has delivered +49.41% over six months versus SPY's -0.54% (+49.95% relative strength). Against a diagnostics and research tools peer group trading in the low-to-mid-20s forward, TMO's 25.0x forward and 21.6x EV/EBITDA represent a modest, defensible premium rather than an extreme one.
The biggest risks that could invalidate the thesis are (1) a stall in the sequential margin climb if 'modest inflation' tied to Middle East tensions pressures gross margins, (2) a slower biopharma and academic funding environment cutting into life science solutions (23% of sales) and CRO growth, and (3) multiple compression given the 4.54x PEG and 27.9x price-to-cash-flow, with the stock already at ~93.8% of its 52-week range. This Buy would upgrade to a stronger conviction add if the stock pulls back toward the $650–$660 support shelf (implying ~13–14% upside to the $752.12 average target) or if Q4 operating margin holds above 19%; it would downgrade to Hold if revenue growth decelerates below 6% or gross margin slips back below 41%. Verdict: fairly-to-fully valued, not cheap — a quality compounder whose forward return depends on earnings delivery rather than further multiple expansion.
Sign up to view all
TMO 12-Month Price Forecast
The forward view is constructive but tempered by valuation. TMO's fundamental trajectory is clearly improving — high-single-digit revenue growth, ~210bps of sequential gross-margin expansion, $7.596 billion of trailing free cash flow, and near-unanimous analyst support — and the low 0.845 beta plus recurring consumables/services mix make it an attractive defensive-growth holding in a weak tape. However, at 32.6x trailing and 25.0x forward PE with a 4.54x PEG, much of the near-term upside to the $752.12 consensus is already captured after a 49.41% six-month run, leaving a modest +8.3% expected return in the base case. The 41% spread between the $590 low and $830 high targets reflects genuine disagreement on margin durability and biopharma funding. I would upgrade to high confidence if Q4 operating margin holds above 19% and revenue growth stays above 8%, and downgrade to neutral if gross margin slips below 41% or growth decelerates below 6%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Thermo Fisher Scientific Inc.'s 12-month outlook, with a consensus price target around $756.52 and implied upside of +5.4% versus the current price.
Average Target
$756.52
27 analysts
Implied Upside
+5.4%
vs. current price
Analyst Count
27
covering this stock
Price Range
$590 - $830
Analyst target range
Coverage is deep and overwhelmingly bullish: 25 analysts rate the stock, with 23 Buy, 3 Hold, and 1 Sell, producing a consensus recommendation of 'strong_buy' and a mean rating of 1.44 (where 1.0 is a strong buy). The average target price of $752.12 implies roughly +8.3% upside from the current $694.76 — a modest but positive expected return that is consistent with a fairly valued quality name rather than a mispriced opportunity. The consensus leans clearly bullish, and the recent institutional ratings flow confirms the tone: Argus reiterated Buy on 2026-10-30, Citigroup reiterated Buy on 2026-10-23, and TD Cowen, Barclays, Stifel, Baird, and Morgan Stanley all maintained Buy/Overweight/Outperform ratings through October — with RBC Capital the lone Sector Perform holdout. There have been no downgrades in the visible recent flow, which is a meaningful signal of conviction following the Q3 print and raised guidance. The target range is wide, from a low of $590 to a high of $830 — a spread of roughly 41% around the average, which signals meaningful dispersion in assumptions rather than uniform consensus. The high target of $830 (about +19.5% upside) likely assumes continued margin expansion toward the low-20s operating margin, sustained high-single-digit revenue growth, successful integration of the 2026 acquisitions, and multiple expansion as the market rewards the AI-efficiency narrative. The low target of $590 (about -15% downside) likely prices in margin compression from inflation and Middle East supply-chain disruption, a slower biopharma funding environment, and multiple contraction back toward the mid-20s. The wide spread, combined with the low beta of 0.845 and the stock trading just 2.4% below its 52-week high, argues for a measured position size: the risk/reward is positive but the easy money has been made, and the stock's recent 49% six-month run means much of the near-term upside to consensus is already reflected in the price.
Drowning in data?
Find the real signal!
Bulls vs Bears: TMO Investment Factors
The bull case currently holds stronger evidence: revenue is genuinely re-accelerating at 9.13% YoY, margins are expanding sequentially across all three quarters of 2026, free cash flow is robust at $7.596 billion, and 23 of 25 analysts are bullish with no recent downgrades. The bear case rests less on fundamentals than on price — a 32.6x trailing PE, a 4.54x PEG, and a 49% six-month run that has already captured much of the near-term upside to the $752.12 consensus target (+8.3%). The single most important tension is whether the sequential margin expansion (gross margin up ~210bps from Q1 to Q3) is durable or a cyclical artifact of easy comps and pricing; if margins hold and grow toward the low-20s operating level, the premium multiple is justified and the stock can grind higher, but if inflation or biopharma funding weakness stalls the margin climb, both the multiple and estimates compress together. Net, this is a high-quality compounder with a positive but modest risk/reward at current levels — the fundamentals support owning it, but the price argues for patience and disciplined entry rather than chasing.
Bullish
- Revenue re-acceleration to 9.1% YoY: Q3 2026 revenue of $12.137 billion grew 9.13% year-over-year versus $11.122 billion in Q3 2025, and the sequential cadence ($11.005B → $11.994B → $12.137B) shows compounding growth rather than a one-off spike. This confirms the post-pandemic destocking hangover has ended and the base business is recovering.
- Sequential margin expansion of ~210bps: Gross margin climbed from 40.67% in Q1 to 41.21% in Q2 to 42.78% in Q3 2026, while operating margin rose from 16.93% to 17.40% to 18.65% over the same span. This operating leverage is the single most important fundamental driver behind the stock's re-rating from ~27x to ~33x trailing PE over two quarters.
- Near-unanimous analyst conviction: 23 of 25 analysts rate TMO a Buy with a consensus 'strong_buy' and mean rating of 1.44, and there have been no downgrades in the visible October flow (Argus, Citigroup, TD Cowen, Barclays, Stifel, Baird, Morgan Stanley all reiterated Buy/Overweight). The average target of $752.12 implies +8.3% upside from $694.76.
- Recurring, consumables-heavy revenue model: Consumables ($4.870B) and services ($5.384B) together dwarf instruments ($1.883B) in Q3 2026, confirming the razor-and-blade model that generates high-visibility recurring cash flow. Trailing free cash flow of $7.596 billion against a $217.9 billion market cap yields roughly 3.5%.
Bearish
- Valuation leaves little margin for error: At 32.6x trailing PE and 25.0x forward PE, TMO trades at a premium to the low-to-mid-20s forward multiple typical of the diagnostics and research tools peer group. The PEG ratio of 4.54x suggests the growth embedded in the multiple is expensive relative to the earnings trajectory.
- Stock extended after 49% six-month run: The +49.41% six-month gain dwarfs the +22.75% one-year return, meaning most of the move is compressed into two quarters, and the stock sits at ~93.8% of its 52-week range. Momentum is decelerating (+4.94% one month vs. +16.96% three months), and the sharp 2026-11-05 reversal from $706.16 to $676.94 shows sensitivity to high-level volatility.
- Interest coverage compressing on M&A debt: Q3 2026 interest expense of $417 million against operating income of $2.263 billion gives coverage of roughly 5.4x, down from over 6x a year ago. The $8.872 billion acquisition spree in Q1 2026 and $3.0 billion of buybacks were partly debt-funded, pushing debt-to-equity to 0.737.
- Wide 41% target dispersion signals uncertainty: Analyst targets range from $590 (-15% downside) to $830 (+19.5% upside) around the $752.12 average — a 41% spread that reflects genuinely divergent assumptions on margin expansion, biopharma funding, and multiple direction. The lone Sell rating and RBC's Sector Perform holdout underscore that not everyone buys the re-rating.
TMO Technical Analysis
TMO is in a powerful, sustained uptrend. The stock has gained 22.75% over the past year and an extraordinary 49.41% over six months, and at $694.76 it sits at roughly 93.8% of its 52-week range (low $435.27, high $712.17) — just 2.4% below the high. That positioning signals strong momentum but also leaves little margin for error: the stock is extended relative to its own range and vulnerable to profit-taking on any disappointment. Notably, the 22.75% one-year gain masks a much steeper recent slope, implying most of the move has been compressed into the last two quarters. Short-term momentum is positive but decelerating relative to the medium-term surge: the 1-month change of +4.94% and 3-month change of +16.96% compare with +49.41% over six months, meaning the rate of advance has cooled even as price makes new highs. Critically, TMO is dramatically outperforming the market — relative strength is +9.93% over one month, +21.87% over three months, and +49.95% over six months versus SPY, which is actually down 4.99% over one month and 4.91% over three months. This is a textbook defensive-growth rotation beneficiary: capital is fleeing a weak tape into high-quality healthcare compounders. The 2.63% single-day gain on the latest session (from $676.94 to $694.76) on volume of roughly 2.09 million shares confirms buyers remain in control, though the sharp intraday reversal on 2026-11-05 (a drop to $676.94 from $706.16) shows the stock is now sensitive to high-level volatility. Key technical levels are well defined: support sits at the 52-week low of $435.27, with a more relevant near-term floor around the $650-$660 shelf that has repeatedly caught pullbacks in September and October; resistance is the 52-week high of $712.17, with the round $700 level acting as an immediate psychological barrier. A clean breakout above $712 would confirm the uptrend and likely trigger momentum-chasing flows, while a failure and breakdown below $650 would signal a deeper mean-reversion move toward the $600 area. With a beta of just 0.845, TMO is roughly 15% less volatile than the market — a favorable characteristic for risk-adjusted position sizing, though it also means the recent 49% six-month run represents an unusually large move for a low-beta name and argues for disciplined trailing stops. The maximum drawdown of -31.45% is a reminder that even defensive compounders can endure painful corrections.
Beta
0.84
0.84x market volatility
Max Drawdown
-31.4%
Largest decline past year
52-Week Range
$435-$728
Price range past year
Annual Return
+22.4%
Cumulative gain past year
| Period | TMO Return | S&P 500 |
|---|---|---|
| 1m | +8.4% | -2.4% |
| 3m | +20.4% | -2.3% |
| 6m | +63.7% | +2.8% |
| 1y | +22.4% | +11.3% |
| ytd | +21.1% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMO Fundamental Analysis
Revenue is re-accelerating convincingly. Q3 2026 revenue came in at $12.137 billion, up 9.13% year-over-year versus $11.122 billion in Q3 2025, and the sequential cadence — $11.005 billion in Q1, $11.994 billion in Q2, $12.137 billion in Q3 — shows steady, compounding growth rather than a one-off spike. The prior-year comparison base was soft (Q3 2025 revenue of $11.122 billion grew only modestly from $10.854 billion in Q2 2025), so the current 9.13% growth reflects genuine underlying recovery plus easier comps. Within the product mix, consumables ($4.870 billion) and services ($5.384 billion) together dwarf instruments ($1.883 billion), confirming the recurring-revenue, razor-and-blade model that underpins the investment case; the services/CRO line is the stickiest and highest-multiple component. Consensus estimates of roughly $59.2 billion in forward revenue imply continued mid-to-high single-digit growth, consistent with a durable but not explosive trajectory. Profitability is solid and improving. Q3 2026 net income was $1.721 billion on a 14.18% net margin, with gross margin of 42.78% — up from 41.21% in Q2 2026 and 40.67% in Q1 2026, a clear sequential expansion. Operating income of $2.263 billion produced an 18.65% operating margin, up from 17.40% in Q2 and 16.93% in Q1, and EBITDA of $2.505 billion (20.64% margin) reflects the operating leverage kicking in as revenue scales. Trailing net margin of 15.12% and operating margin of 18.20% are healthy for the tools sector, and the sequential margin climb — gross margin up roughly 210 basis points from Q1 to Q3 — is the single most important fundamental data point supporting the re-rating. The balance sheet and cash generation are strong but not pristine. Debt-to-equity of 0.737 and a current ratio of 1.89 indicate comfortable liquidity, while trailing free cash flow of $7.596 billion against a $217.9 billion market cap yields roughly 3.5% — respectable but not cheap for a low-beta name. ROE of 12.61% and ROA of 5.19% are moderate, reflecting the capital-intensive acquisition-driven model; the company deployed $8.872 billion on acquisitions in Q1 2026 alone and repurchased $3.0 billion of stock, funded partly by debt. Interest coverage of roughly 5.4x (Q3 interest expense of $417 million against operating income of $2.263 billion) is adequate but has compressed from over 6x a year ago, and the Q1 acquisition spree pushed cash down to $3.28 billion before recovering to $5.494 billion by Q3. The company generates enough operating cash ($2.55 billion in Q3) to fund capex ($437 million) and dividends ($174 million) internally, but large-scale M&A still requires external financing — a structural feature, not a red flag, for this serial acquirer.
Quarterly Revenue
$12.1B
2026-09
Revenue YoY Growth
+9.1%
YoY Comparison
Gross Margin
42.8%
Latest Quarter
Free Cash Flow
$7.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMO Overvalued?
Because Thermo Fisher is solidly profitable (Q3 2026 net income of $1.721 billion), the PE ratio is the appropriate primary metric. The stock trades at a trailing PE of 32.6x versus a forward PE of 25.0x — a roughly 23% compression that implies the market expects meaningful earnings growth, consistent with consensus EPS of $37.24 for the forward period. That forward/trailing gap is the crux of the valuation debate: investors are paying up today for earnings that must materialize tomorrow, and any guidance miss would compress both the multiple and the estimate simultaneously. On a PEG basis the picture is less flattering at 4.54x, suggesting the growth embedded in the multiple is expensive relative to the earnings trajectory. Against the broader medical diagnostics and research tools peer group, TMO's 32.6x trailing PE and 21.6x EV/EBITDA sit at a premium — the sector typically trades in the low-to-mid 20s on forward earnings, and TMO's forward PE of 25.0x represents a modest premium to that benchmark rather than an extreme one. The premium is defensible given TMO's scale leadership, recurring consumables mix, and above-peer margin profile (18.2% operating margin), but it is not a bargain. The 4.89x price-to-sales and 4.08x price-to-book are moderate for a high-quality compounder, while the 27.9x price-to-cash-flow ratio is elevated and reflects the capital-intensive acquisition model. Historically, TMO's PE has ranged from the low 20s to the low 40s over the past several years; the current 32.6x trailing sits in the upper-middle of that band, well above the 27.4x seen in Q2 2026 and the 26.7x in Q1 2026, but below the 36-42x peaks of 2024. The re-rating from ~27x to ~33x over two quarters reflects the market pricing in the margin-expansion and growth-recovery story — optimistic but not euphoric. The stock is neither a deep-value opportunity nor a bubble; it is a fairly-to-fully valued quality compounder whose return from here depends on earnings delivery rather than multiple expansion.
PE
32.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 24x~43x
vs. Industry Avg
35.2x
Industry PE ~35.2x*
EV/EBITDA
21.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the acquisition-driven capital model and compressing interest coverage. TMO spent $8.872 billion on acquisitions in Q1 2026 alone and repurchased $3.0 billion of stock, partly debt-funded, leaving debt-to-equity at 0.737 and interest coverage at roughly 5.4x (Q3 interest expense of $417 million vs. $2.263 billion operating income), down from over 6x a year ago. The 14.18% net margin and 18.65% operating margin are healthy but depend on continued revenue scaling to deliver operating leverage; a stall in the sequential gross-margin climb (40.67% → 41.21% → 42.78% across Q1–Q3) would hit earnings disproportionately given the 32.6x trailing multiple. Revenue concentration in life science solutions (23%) and lab products/CRO (the remainder) ties results to biopharma and academic funding cycles, and the capital-intensive model means large M&A will keep requiring external financing. Market and competitive risks are primarily valuation-driven. At 32.6x trailing and 25.0x forward PE versus a peer group in the low-to-mid-20s forward, TMO carries a premium that assumes continued margin expansion and high-single-digit growth; any deceleration compresses both the multiple and estimates simultaneously, a double hit. The PEG of 4.54x and price-to-cash-flow of 27.9x are elevated, and the stock's 49.41% six-month run against SPY's -0.54% means it is now a crowded defensive-growth trade vulnerable to sector rotation if the market broadens. Management's flagged 'modest inflation' risk from Middle East tensions and a slower biopharma funding environment are the most concrete external threats, while the low beta of 0.845 cushions but does not eliminate drawdowns. The worst-case scenario is a margin-expansion reversal combined with multiple compression: if inflation pressures gross margins and biopharma funding slows revenue growth back toward mid-single digits, the stock could de-rate toward the mid-20s forward multiple, aligning with the analyst low target of $590 — roughly -15% from the current $694.76. A deeper mean-reversion move toward the $600 area (below the $650-$660 support shelf) is plausible on a technical breakdown, and the historical max drawdown of -31.45% shows even this defensive compounder can endure painful corrections; a full retrace to the 52-week low of $435.27 would represent roughly -37% downside, though that would require a severe fundamental deterioration beyond current base-case assumptions.
FAQ
The most severe risk is valuation compression: at 32.6x trailing PE, 25.0x forward PE, and a 4.54x PEG, the stock carries a premium that assumes continued margin expansion, and any deceleration would compress both the multiple and estimates simultaneously. Second is margin durability — gross margin climbed ~210bps from 40.67% in Q1 to 42.78% in Q3 2026, and management has flagged 'modest inflation' tied to Middle East tensions that could reverse that climb and disproportionately hit earnings. Third is financial leverage from the acquisition model: $8.872 billion of Q1 2026 acquisitions plus $3.0 billion of buybacks left debt-to-equity at 0.737 and interest coverage at roughly 5.4x (Q3 interest expense of $417 million vs. $2.263 billion operating income), down from over 6x a year earlier. Fourth is end-market concentration — life science solutions (23% of sales) and CRO services depend on biopharma and academic funding, and a funding slowdown would cut growth back toward mid-single digits. Ranked by severity: valuation compression first, margin reversal second, funding/end-market risk third, and balance-sheet leverage fourth.
The 12-month forecast is split into three scenarios. The base case (55% probability) targets $720–$770, anchored on the $752.12 analyst average, assuming high-single-digit revenue growth, stable-to-improving margins, and a forward PE holding near 25.0x. The bull case (25% probability) targets $790–$830, aligned with the $830 analyst high, and requires operating margin pushing into the low-20s, high-single-digit growth on biopharma funding recovery, and modest multiple expansion. The bear case (20% probability) targets $590–$650, aligned with the $590 analyst low, and assumes inflation pressures gross margins, biopharma funding slows growth to mid-single digits, and the multiple compresses toward the mid-20s. The base case is most likely, and its key assumption is that the sequential margin expansion seen across Q1–Q3 2026 proves durable rather than a cyclical artifact of easy comps and pricing.
TMO is fairly-to-fully valued, not cheap. The trailing PE of 32.6x compares with a forward PE of 25.0x, implying roughly 23% earnings growth is already embedded in consensus forward EPS of $37.24, and the PEG of 4.54x suggests investors are paying a rich price for that growth. Against a diagnostics and research tools peer group trading in the low-to-mid-20s on forward earnings, TMO's 25.0x forward and 21.6x EV/EBITDA represent a modest, defensible quality premium rather than an extreme one, supported by its 18.2% operating margin and scale leadership. Historically the stock's PE has ranged from the low 20s to the low 40s, and the current 32.6x trailing sits in the upper-middle of that band — well above the ~27x seen in Q1–Q2 2026 but below the 36–42x peaks of 2024. The market is therefore pricing in successful execution of the margin-expansion and growth-recovery story; if that delivery falters, the multiple has room to compress toward the mid-20s, which is precisely what the $590 bear-case target reflects.
From a risk/reward standpoint TMO is a reasonable but not compelling buy at $694.76: the average analyst target of $752.12 implies only +8.3% upside, while the analyst low target of $590 implies -15% downside, so the reward-to-risk is roughly balanced rather than asymmetric. The quality case is strong — 23 of 25 analysts rate it Buy with a 'strong_buy' consensus, revenue grew 9.13% YoY in Q3 2026, operating margin expanded from 16.93% to 18.65% across Q1–Q3, and free cash flow of $7.596 billion supports the dividend and buyback. The biggest downside risk is multiple compression: at 32.6x trailing and 25.0x forward PE with a 4.54x PEG, the stock is priced for continued margin expansion, and a stall would hit both estimates and the multiple. It is a good buy for patient, long-horizon investors seeking low-volatility (beta 0.845) healthcare exposure, particularly on a pullback toward the $650–$660 support shelf, but less attractive for anyone chasing the 49.41% six-month move at current levels.
TMO is primarily a long-term holding. It is a mature, large-cap ($217.9 billion market cap) life sciences compounder with a low beta of 0.845, a token dividend (0.29% yield, 9.4% payout ratio), and high earnings visibility from its recurring consumables and services mix — characteristics that favor multi-year ownership rather than tactical trading. The 49.41% six-month gain versus SPY's -0.54% shows the stock can move sharply, but the -31.45% historical max drawdown and the sharp 2026-11-05 reversal from $706.16 to $676.94 illustrate that short-term entries carry real timing risk at these extended levels. A concrete minimum holding period of 2–3 years is appropriate to let high-single-digit revenue growth and operating leverage compound, and to ride out any multiple compression. Short-term traders could work the $650–$660 support and $712 resistance range, but the risk/reward for that approach is inferior to simply accumulating on weakness for the long haul.